An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.

Phase 1

Novartis Pharmaceuticals

Camptothecin